From the outset, the charity has been a relentless force for change, ensuring that patients are not defined by their diagnosis but empowered by cutting-edge care and research.
The charity’s impact on the healthcare landscape has been transformative. By pioneering the Clinical Service Excellence Programme (CSEP), Myeloma UK has set a gold standard for treatment, accrediting hospitals that deliver exceptional, patient-focused care. This initiative ensures that wherever a patient lives, they can expect best-practice support that prioritises their quality of life. Furthermore, through its dedicated advocacy work, the charity has successfully secured NHS access to game-changing treatments, including innovative quadruplet therapies and immunotherapies that were previously out of reach.
Beyond clinical standards, Myeloma UK is driving the science that will one day lead to a cure. Its MyeTRIAL Partnership, in collaboration with the University of Leeds Clinical Trials Research Unit, puts people living with myeloma in the driving seat of clinical trial design.
“Myeloma UK gave me clarity when I felt lost. Their advocacy meant I could access a new drug that gave me my life back, allowing me to see my grandson start school – a milestone I thought I’d miss.”
- Patient supported by the charity
By amplifying the patient voice at the highest levels of decision-making and relentlessly pushing the boundaries of medical research, Myeloma UK is reshaping the future. It strives for a world where myeloma is no longer a life-limiting condition, but a manageable one, ensuring every patient has the chance to live a full and meaningful life.
Learn more about their work
here.
